What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.